New Treatment Approach for Rheumatoid Arthritis Shows Promise in Trial

Results of a Phase 2a clinical trial suggest that peresolimab, an antibody that stimulates the human death protein 1 (PD-1) pathway, could be a promising new approach for the treatment of rheumatoid arthritis.

Related Keywords

Eli Lilly ,Ajay Nirula ,Jay Tuttle ,American College Of Rheumatology ,Technology Network ,Company Lilly ,New England Journal ,Disease Activity Score ,